Issa Mohamad  To compare outcomes and toxicity of two standard treatment approaches of advanced nasopharyngeal carcinoma (NPC).  Between 2010 and 2016, patients with NPC, stage II-IVa, treated with induction chemotherapy (IC) (TPF), followed by concurrent chemoradiotherapy (CCRT) (induction group), or CCRT, followed by adjuvant chemotherapy (AC) (PF) (no-induction group), were retrospectively reviewed. CCRT included platinum-based chemotherapy with intensity-modulated radiotherapy. Survival outcomes, the pattern of failures, toxicity, and predictors for survival outcomes were evaluated.  A total of 110 patients were included, 65 in the induction group and 45 in the no-induction group. There were no significant differences in the DFS and overall survival (OS) at 3 years between the two groups. On multivariate analysis, performance status (1 vs. 0) predicted worse OS. The 3-year cumulative incidence rates for local, regional, and distant failures were 58.5% (95% confidence interval [CI]: 8.4-89%), 58.00% (95% CI: 8-88.8%), and 63.90% (95% CI: 14.1-90.2%), respectively. IC had more frequent acute grade (G) II anemia (13 vs. 1,  < 0.01), late G II brain toxicity (4 vs. 1,  < 0.01), and late G II dysphagia (32 vs. 11,  = 0.01).  Survival outcomes were comparable between the two groups. IC had more frequent acute G II anemia and late G II brain and esophageal toxicities.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803531PMC
http://dx.doi.org/10.1055/s-0042-1742724DOI Listing

Publication Analysis

Top Keywords

standard treatment
8
treatment approaches
8
advanced nasopharyngeal
8
nasopharyngeal carcinoma
8
induction group
8
no-induction group
8
survival outcomes
8
comparison standard
4
approaches locoregionally
4
locoregionally advanced
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!